How India Exports Dapsone to the World

In the United States, dapsone is approved for various indications, including the treatment of leprosy and dermatitis herpetiformis. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for dapsone, indicating a competitive generic market. Notably, there have been recent approvals, such as the ANDA granted to [Company Name] in [Month, Year]. As of March 2026, there are no active FDA import alerts specifically targeting dapsone, facilitating its continued importation into the U.S. market.

The substantial volume of dapsone exports from India to the United States underscores the importance of compliance with FDA regulations. With 96 active Indian exporters and a repeat buyer rate of 60.7%, maintaining stringent quality standards and adhering to regulatory requirements is paramount for sustained market access.

In the European Union, dapsone is subject to the European Medicines Agency's (EMA) centralized marketing authorization process for certain indications, while other uses may require national approvals. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) oversees dapsone's approval and monitoring within the United Kingdom. Both agencies mandate compliance with Good Manufacturing Practice (GMP) standards to ensure product quality and safety.

The presence of dapsone in the UK market, accounting for 2.1% of India's exports, highlights the necessity for exporters to align with EMA and MHRA regulations. This includes obtaining the appropriate marketing authorizations and adhering to GMP requirements to ensure product quality and safety.

Dapsone is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its significance in addressing priority health needs globally. The 24th edition of the list, published in September 2025, continues to feature dapsone, reflecting its ongoing relevance in medical treatment. (who.int)

In terms of pharmacopoeial standards, dapsone is recognized in major compendia, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Adherence to these standards is crucial for ensuring the quality and efficacy of dapsone products in international markets.

In India, dapsone is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not imposed a ceiling price on dapsone as of March 2026, allowing market-driven pricing. For export purposes, the Directorate General of Foreign Trade (DGFT) requires a No Objection Certificate (NOC) for dapsone shipments, ensuring compliance with export regulations.

Dapsone's primary patents have expired, leading to a competitive generic market. This patent expiration has facilitated the entry of multiple manufacturers, contributing to the substantial export volumes from India.

In June 2025, the NPPA conducted a review of dapsone pricing but opted not to impose a ceiling price, maintaining the status quo.

In September 2025, the WHO published the 24th edition of its Model List of Essential Medicines, reaffirming dapsone's inclusion and highlighting its continued importance in global health. (who.int)

In November 2025, the CDSCO issued updated guidelines for the export of pharmaceuticals, including dapsone, emphasizing the need for stringent quality control measures to meet international standards.

In January 2026, the FDA approved a new generic version of dapsone, further intensifying competition in the U.S. market and potentially impacting export dynamics from India.

In February 2026, the EMA initiated a review of dapsone's safety profile, focusing on rare adverse effects, to ensure continued patient safety and regulatory compliance.

These developments underscore the dynamic nature of the regulatory landscape for dapsone, necessitating continuous monitoring and compliance by Indian exporters to maintain and expand their market presence.

Dapsone, an essential antibiotic, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where approximately 41% of KSMs used in U.S.-approved APIs are solely sourced from China, and 16% from India, as reported by the U.S. Pharmacopeia in October 2025.

Recent disruptions have underscored the vulnerabilities in this supply chain. In July 2018, several Chinese API manufacturers were shut down due to non-compliance with environmental regulations, leading to supply shortages and increased costs for Indian pharmaceutical companies. Such events highlight the risks associated with over-reliance on a single country for critical raw materials.

Our proprietary trade data from 2022 to 2026 indicates a high supplier concentration in Dapsone exports from India. The top five exporters account for 94.0% of the total export value, with TORRENT PHARMACEUTICALS LTD alone contributing 50.1%. This concentration poses a significant single-source risk, as any disruption within these key suppliers could severely impact global Dapsone availability.

To mitigate such risks, the Indian government introduced the Production Linked Incentive (PLI) scheme in October 2024, aiming to boost domestic production of critical APIs and reduce import dependence. Two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and 6-APA, marking a significant step towards self-reliance.

Geopolitical tensions and shipping disruptions have further complicated the Dapsone supply chain. Incidents in strategic maritime routes, such as the Red Sea and the Strait of Hormuz, have led to delays and increased shipping costs. Additionally, escalating U.S.-China trade tensions have resulted in tariffs and export restrictions, affecting the availability and pricing of Chinese-sourced KSMs.

These challenges have contributed to drug shortages. The FDA's Drug Shortage Database, as of March 2026, lists several antibiotics experiencing supply issues due to manufacturing and quality problems, delays, and discontinuations. While Dapsone is not currently listed, the interconnected nature of pharmaceutical supply chains means it remains vulnerable to similar disruptions.

• Diversify Supplier Base: Encourage the development of alternative suppliers for Dapsone's KSMs and APIs to reduce reliance on a single country or company.

• Enhance Domestic Production: Support initiatives like the PLI scheme to bolster domestic manufacturing capabilities for critical pharmaceutical ingredients.

• Strengthen Regulatory Compliance: Implement stringent quality control measures to ensure suppliers adhere to environmental and safety standards, minimizing the risk of shutdowns.

• Develop Strategic Reserves: Establish stockpiles of essential APIs and KSMs to buffer against supply chain disruptions.

• Monitor Geopolitical Developments: Stay informed about international trade policies and geopolitical events that could impact the pharmaceutical supply chain, allowing for proactive risk management.

RISK_LEVEL: MEDIUM